[Eli Lilly and Q3 2026 Earnings Call] Lilly Raises 2026 Revenue Guidance to $91–92 Billion After Mounjaro and Zepbound Combined Revenue Tops $16 Billion

Eli Lilly reported Q3 2026 revenue of $24.5B, up 39% YoY, and raised full-year guidance to $91-92B. Mounjaro and Zepbound combined for $16B in revenue. CEO Dave Ricks cited strong growth in new pharmaceutical categories. Non-GAAP EPS was $7.48, including $4.57 in acquired R&D charges. The company expects continued volume growth but notes 2026 benefited from $2B in one-time items.

Original reporting
Published Oct 29, 2026, 4:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 4:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LLY
Bullish
high confidence
Mentioned
$LLY
Relevance
9/10
AlphAI data visualization · based on finance.biggo.com
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

The guidance lift is likely to trigger buying interest and could spark re‑rating by analysts.

02

Market read

First‑report earnings guidance raise for a large‑cap pharma; high relevance for equity traders.

03

What to watch

Net realized price headwinds and upcoming one‑time items could temper growth.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Eli Lilly reported Q3 2026 results with 39% YoY revenue growth and announced a significant guidance raise.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly raised its FY2026 revenue guidance to $91‑92 B after Q3 revenue of $24.5 B, driven by $16 B from Mounjaro and Zepbound.

Expected impact

upward pressure as investors price in higher revenue outlook

Evidence & confidence

The $10 B guidance increase is material for a large‑cap pharma and was disclosed for the first time.

Market effects

Boosts outlook for the broader biotech/pharma sector, especially GLP‑1 peers.

Positive for US healthcare stocks; may lift European pharma ADRs.

Reinforces bullish bias on obesity‑treatment market worldwide.

Counterpoint

Guidance may be overstated if one‑time milestone items fade; price could correct on earnings volatility.

Key entities

  • Eli Lilly

    US‑listed pharmaceutical giant (LLY).

  • Mounjaro

    Lilly's obesity/diabetes drug contributing major revenue.

  • Zepbound

    Lilly's weight‑loss therapy adding to revenue growth.

Related articles

$NVOLow

GLP-1 vision warning: Could demand be affected?

The FDA requires GLP-1 drugs to carry warnings about a potential increased risk of NAION, a condition that can cause vision loss. Analysis showed 6.4 cases per 100,000 person-years among users, though no causal link has been established. Experts believe the warnings will have limited impact on demand. Novo Nordisk and Eli Lilly, manufacturers of GLP-1 drugs, responded to the FDA's requirements, emphasizing patient safety and the lack of specific findings related to their medicines.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$LLYMed

ACR: Retatrutide Beneficial in Adults With Painful Knee OA, Obesity

A study published in the New England Journal of Medicine found that retatrutide, developed by Eli Lilly, significantly reduced knee pain and body weight in adults with painful knee osteoarthritis and obesity compared to placebo. The trials showed mean WOMAC pain score reductions of -3.96 and -3.74 for 9mg and 12mg doses, respectively, versus -2.12 for placebo, and weight reductions of -20.0% and -23.7% versus -4.6%. Serious adverse events were more common with retatrutide.

$LLYMed

Health Canada approves Eli Lilly’s daily Foundayo pill for weight loss

Health Canada approved Eli Lilly's daily oral weight-loss pill, Foundayo, for adults with obesity or related conditions. The drug, expected in January, competes with Lilly's injectables and Novo Nordisk's Rybelsus. Foundayo offers meal flexibility and differs chemically from other GLP-1 drugs. Pricing and insurance coverage will impact patient choices, with clinical trials showing varying weight-loss results.

$NVOHigh

What to know about the new GLP-1 pills now on sale

Novo Nordisk's Wegovy and Lilly's Foundayo, oral GLP-1 weight loss pills, are now available in Australia. Experts anticipate increased demand but caution about long-term effects and misuse. Prices range from $250 to $395 monthly, comparable to injectable versions. Availability varies by pharmacy.